Freeze-drying, or lyophilisation, is the pharmaceutical manufacturing process that removes frozen water from a product under vacuum by sublimation, leaving a stable solid powder, and demand for it is rising as the number of biological pharmaceuticals grows, according to a trade-press feature published by Manufacturing Chemist on 10 January 2023. The report centres on Optima pharma GmbH of Gladenbach, Hesse, Germany, a specialist in freeze-drying systems, which has doubled its production area in Gladenbach and almost doubled its workforce since 2014. For the peptide therapy and research peptide sector, the story matters because lyophilisation is the step that turns sensitive peptide molecules into storable active ingredients — the powder form in which many peptides are shipped, stored and later reconstituted.
What happened: freeze-drying capacity expands as biologics grow
The feature describes freeze-drying as a routine process regularly employed to manufacture biopharmaceuticals and many other drugs, used to convert antibiotics, hormones, antibodies, RNA-based vaccines and other pharmaceutical drugs into a storable, solid powder form known as cake. Stephan Reuter, Managing Director of Optima pharma GmbH, told the publication that most patients receive these drugs in liquid form rather than as tablets because the sensitive molecules are not particularly stable in liquid form and can change in structure and lose their effectiveness.
Reuter is quoted saying that freeze-drying is a safe method proven to convert even sensitive biopharmaceuticals into a stable and storable product, in contrast to boiling, which irreversibly damages product at sustained high temperatures and can also lose active material as vapour. The article attributes rising demand to factors including the coronavirus pandemic and the growing number of biological pharmaceuticals and their transport, and reports that Optima Pharma has doubled its production area in Gladenbach, that its employee count has almost doubled since 2014, and that its export share is more than 85%.
Key numbers: how much of the drug pipeline depends on lyophilisation
The most quotable figure in the report is an estimate from Reuter: approximately one fifth of the top 100 pharmaceuticals are freeze-dried, and for biologics that figure rises to almost half. That estimate is an attributed expert statement rather than an independently audited market statistic, but it frames why equipment capacity and process efficiency have become commercially significant.
Freeze-drying is also energy intensive. According to Reuter, stainless-steel systems weighing up to 30 tons must first be sterilised with steam at up to 130 °C, cooled to –70 °C, placed under vacuum and then reheated to 130 °C again. The article reports that dedicated refrigeration and new innovative cooling agents save 10–20% in energy costs, and that, considering shorter process times, freeze-drying systems can consume up to 25% less energy than before these measures were implemented. Those savings figures are presented without a named study or measurement methodology, so they should be read as vendor-linked claims rather than audited benchmarks.
| Metric | Figure | Attribution |
|---|---|---|
| Top 100 pharmaceuticals that are freeze-dried | ~1 in 5 | Stephan Reuter, Optima pharma |
| Biologics that are freeze-dried | Almost half | Stephan Reuter, Optima pharma |
| Energy cost saving from new cooling agents | 10–20% | Article, no study named |
| Energy reduction including shorter process times | Up to 25% | Article, no study named |
| Weight of stainless-steel freeze-drying systems | Up to 30 tons | Stephan Reuter, Optima pharma |
| Sterilisation and reheating temperature | Up to 130 °C | Stephan Reuter, Optima pharma |
| Cooling temperature | –70 °C | Stephan Reuter, Optima pharma |
| Optima Pharma export share | More than 85% | Article |
Why it matters for peptide therapy and research peptides
Peptides are small proteins consisting of several amino acids linked by peptide bonds, and the article notes their numerous potential applications in molecular biology, immunology and medicine, including opportunities in cancer and individualised vaccines. Reuter is quoted saying peptides are highly effective and exhibit high selectivity and specificity with regard to their biological targets, which he says offers promising prospects for novel drug designs. That is an expert opinion on molecular promise, not evidence of clinical efficacy for any specific peptide.
For the peptide supply chain, the practical point is stability. A peptide API that degrades in solution cannot be warehoused or shipped economically, so lyophilisation is often the step that converts a bulk active ingredient into a storable solid. Reuter describes the final stage as solid-liquid separation, with the freeze-dried product or cake obtained at the customer’s facility in containers that resemble baking trays, and the final stable peptides available in milligrams to kilograms as a fine powder and used as active ingredients for various pharmaceuticals.
This is where quality documentation becomes decisive. Buyers of peptide API should distinguish between a batch certificate of analysis, chromatographic purity results and assay content, because an HPLC area percentage does not by itself establish identity, potency, sterility or suitability for human use. A freeze-dried powder that looks uniform can still differ in residual moisture, counterion content or impurity profile, and those attributes belong in the specification and release testing rather than in a marketing claim. Industry observers note that as more peptide programs move from research quantities to gram and kilogram scale, the drying step and its documentation become a supply-continuity issue, not merely a formulation detail.
Research and market context: smaller batches, smaller machines
Reuter identifies several trends shaping how drug production facilities are built: personalised medicines, mRNA, and cell and gene technologies. According to the report, these are pushing facilities toward fewer large systems and a focus on smaller batches with smaller equipment, and biopharmaceutical companies — and even hospital pharmacies — want multiple freeze-dryers with a reduced footprint. He also says there is no off-the-shelf freeze-dryer that can accommodate every requirement, because equipment must be adapted to the product, the customer’s needs and on-site conditions.
The article reports that Optima is involved in controlled nucleation, a development area focused on the difficult-to-control freezing step, especially for highly purified products. In controlled nucleation, additional pressure is created in the system and released quickly, resulting in the formation of very homogenous ice crystals and, at the same time, accelerating the drying process. The magnitude of that acceleration is not quantified in the report, and no independent data is presented, so the claim should be treated as a described process effect rather than a validated performance benchmark.
For clinics, telemedicine operators and research peptide businesses, the read-across is indirect but real. Lyophilisation capacity, energy cost and equipment footprint influence the cost and lead time of finished peptide powders, including the lyophilised formats supplied in vials, dual-chamber cartridges and injection pens. Nothing in the report establishes that any specific peptide product is approved, and research peptides remain for research use only; where a peptide is a prescription medicine, prescribing and medical supervision apply. 多肽供应链资源网 as a provider in the industry domain tracks these manufacturing and sourcing questions for supply chain professionals.
What comes next: what to watch
Reuter is confident that the positive trend will continue, and the article states that today’s freeze-drying process has become much more energy efficient and increasingly diverse compared with just a few years ago. Readers tracking the peptide supply chain should watch three things: whether energy-saving and controlled-nucleation claims are backed by published performance data; whether smaller-footprint systems actually reach hospital pharmacies and smaller CDMOs; and whether buyers of lyophilised peptide API tighten their requests for batch-specific analytical data, impurity profiles and stability documentation.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. Additional supply chain and sourcing intelligence is available through peptidescm.
FAQ
What is freeze-drying in peptide manufacturing?
Freeze-drying, or lyophilisation, removes frozen water from a product under vacuum by sublimation while the temperature is gradually raised, leaving the active ingredient as a fine powder. It is used because many sensitive biopharmaceutical molecules are not particularly stable in liquid form.
Does freeze-drying make a peptide approved or safe for human use?
No. Drying is a manufacturing step, not a regulatory approval. A lyophilised peptide still requires the applicable regulatory pathway, and research-use-only materials should not be assumed suitable for human administration.
Why is freeze-drying considered expensive?
The equipment is energy intensive: systems weighing up to 30 tons are sterilised with steam at up to 130 °C, cooled to –70 °C, placed under vacuum and reheated to 130 °C. The report cites energy cost savings of 10–20% from new cooling agents and up to 25% overall with shorter process times.
How much of the pharmaceutical market relies on lyophilisation?
According to Stephan Reuter of Optima pharma, approximately one fifth of the top 100 pharmaceuticals are freeze-dried, rising to almost half for biologics. This is an attributed estimate, not an audited market statistic.
Comments